Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change

L.J.M. Boonman-de Winter1 · M.J. Cramer2 · A.W. Hoes3 · F.H. Rutten3

Published online: 23 February 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Undetected heart failure appears to be an important health problem in patients with type 2 diabetes and aged ≥ 60 years. The prevalence of previously unknown heart failure in these patients is high, steeply rises with age, and is overall higher in women than in men. The majority of the patients with newly detected heart failure have a preserved ejection fraction. A diagnostic algorithm to detect or exclude heart failure in these patients with variables from the medical files combined with items from history taking and physical examination provides a good to excellent accuracy. Annual screening appears to be cost-effective. Both unrecognised heart failure with reduced and with preserved ejection fraction were associated with a clinically relevant lower health status in patients with type 2 diabetes. Also the prognosis of these patients was worse than of those without heart failure. Existing disease-management programs for type 2 diabetes pay insufficient attention to early detection of cardiovascular diseases, including heart failure. We conclude that more attention is needed for detection of heart failure in older patients with type 2 diabetes.

Keywords Heart failure · Type 2 diabetes · Primary care · Screening · Preserved ejection fraction

Introduction

At present, disease management of patients with type 2 diabetes (T2DM) is mainly focussed on glucose regulation, blood pressure and lipid control, prevention of diabetic ulcers, and the early detection of specific micro-vascular problems, typically albuminuria and retinopathy. Despite increased emphasis on lipid and blood pressure control in the last decade, premature cardiovascular diseases remain the main cause of mortality in patients with T2DM [1]. It is therefore surprising that current disease management programs do not yet prioritise early detection of cardiovascular diseases.

In view of this, we hypothesised that especially older patients with T2DM may have unsuspected and uncomplicated heart failure. Especially heart failure with preserved ejection fraction (HFpEF) is expected to be highly prevalent, because in the early stages of this subtype of heart failure, symptoms often only occur after exercise, and signs of fluid retention can be inconspicuous. The risk of remaining undetected and being wrongly labelled as e.g. chronic obstructive pulmonary disease (COPD) is high for HFpEF, the more because echocardiography is not readily available in primary care, while echocardiography is essential for establishing the diagnosis of HFpEF.

Heart failure in type 2 diabetes in the Netherlands

Our group showed that the prevalence of previously unknown heart failure in patients with T2DM aged ≥ 60 is high (27.7%), steeply rises with age, and is overall higher in women than in men (31.0 vs. 24.8%, respectively). The majority (83%; i.e. 22.9% of all T2DM patients aged ≥ 60 years) had HFpEF, while 17% (i.e. 4.8% of all T2DM patients ≥ 60 years) had previously unrecognised...
heart failure with reduced ejection fraction (HFrEF) [2]. To unmask early disease manifestations we developed a diagnostic algorithm to detect or exclude heart failure in T2DM patients aged ≥60 years [3]. Variables that can easily be assessed in the electronic medical files of primary care facilities in combination with items from history taking and physical examination provided a good to excellent accuracy for detection or exclusion of heart failure in such patients with a C-statistic of 0.82; 95% CI 0.79–0.86. We rounded the coefficients of the clinical model to the nearest integer after shrinkage to construct this diagnostic algorithm. Variables included were age over 75 (1 point), a history of ischaemic heart disease (1 point), a history of transient ischaemic attack or stroke (1 point), dyspnoea or fatigue (2 points), reported ankle oedema or nocturia (1 point), intermittent claudication (1 point), and signs of fluid overload (1 point). Patients with more than three points have a higher risk of heart failure of more than 20%. Both electrocardiography and natriuretic peptides had independent added value beyond the clinical model and increased the C-statistic to 0.86; 95% CI 0.83–0.89 [3].

Does this make screening cost-effective? Annual screening for heart failure of patients with T2DM aged ≥60 appears to be cost-effective. A model with information from the electronic medical records (age and comorbidities) and suggestive symptoms of heart failure performed best for a low willingness-to-pay threshold of € 20,000 per quality-adjusted life-year, a commonly used threshold in Europe. The potential cost-effectiveness would be better if convincing mortality-reducing treatment for HFpEF were to become available in the near future [4].

Already at the time of screening, both screen-detected HFrEF and HFpEF were associated with a clinically relevant lower health status than patients with T2DM without heart failure. This persisted during the 1-year follow-up period. Patients with T2DM without screen-detected or known heart failure had a similar health status to age- and gender-matched subjects from the population at large [4, 5]. Patients with T2DM and screen-detected heart failure also had a worse prognosis than T2DM patients without such a diagnosis. After adjustment for age and gender, the hazard ratio for all-cause mortality was 1.5 (95% CI 0.8–2.7), for cardiac hospitalisations 2.2 (95% CI 1.5–3.3), and for the composite endpoint combining these two 1.8 (95% CI 1.3–2.6). The negative prognostic effect was most evident in those with HFrEF. The hazard ratio adjusted for age and gender for the combined endpoint of all-cause mortality and cardiac hospitalisations was 3.7 (95% CI 2.2–6.3) for HFrEF and 1.5 (95% CI 1.0–2.2) for HFpEF compared with those without screen-detected heart failure [6]. Note the mean NT-proBNP at diagnosis was significantly higher for patients with HFrEF than for patients with HFpEF: 104 vs. 33 pmol/l respectively; p<0.001.

### Screening patients with T2DM older than 60 years for heart failure

It seems reasonable to distinguish between screening for HFrEF and HFpEF, because both the prevalence of unrecognised disease and the availability of evidence-based interventions for reducing morbidity and mortality differ considerably. The prevalence is much higher for HFpEF, while convincing evidence-based therapy is only available for HFrEF.

When the screening criteria of Wilson and Jungner are applied, it seems that most criteria for screening are fulfilled for HFrEF, but not for HFpEF (Table 1; [7]). For HFpEF, there is much more uncertainty. For example, its natural history is less clear, and also the underlying pathophysiological pathways have not been fully elucidated, although recently the understanding of possible causal mechanisms has increased [8]. Important questions remain, e.g. about the exact mechanisms involved in the development of “diabetic cardiomyopathy” [9]. Furthermore, there is still an ongoing discussion on the exact echocardiographic criteria that should be fulfilled to establish HFpEF, and this hampers the diagnosis. Finally, treatment of HFpEF is focused on reduction of symptoms of fluid overload and comorbid conditions [10]. Diuretics are the only option for symptom relief, but their prognostic effects have never been adequately evaluated. Other drugs, including beta-blockers, angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers and mineralo-corticoid inhibitors have been tested in ran-

### Table 1 Principles of early detection of, or screening for disease of Wilson and Jungner, 1968, applied to detection of heart failure in patients with T2DM aged 60 years or over

| Criteria met for HFrEF | Criteria met for HFpEF |
|------------------------|------------------------|
| 1. The condition sought should be an important health problem | + |
| 2. There should be an accepted treatment for the disease | + +/− |
| 3. Facilities for diagnosis and treatment should be available | +/− +/− |
| 4. There should be a recognisable latent or early symptomatic stage of the disease | + +/− |
| 5. There should be a suitable test or examination for the disease | + +/− |
| 6. The test should be acceptable to the population | + +/− |
| 7. The natural history of the disease should be adequately understood | + +/− |
| 8. There should be an agreed policy on whom to treat as patients | + +/− |
| 9. The total cost of finding a case should be economically balanced in relation to medical expenditure as a whole | + +/− |
| 10. Case-finding should be a continuous process, not just a ‘once and for all’ project | + +/− |

HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, + fully met; +/− partly met, − does not meet the criterion.
domised trials in patients with HFP EF, mainly in addition to diuretics, but with disappointing results, with at best a statistically non-significant relative risk reduction on all-cause mortality of around 10% [10]. These results can be further ‘downgraded’ because a substantial number of the included patients had a left ventricular ejection fraction in the range of 40–50%, and many consider this to be HFrEF, and not HFP EF. Thus, screening all T2DM patients aged ≥60 for HFrEF seems more reasonable according to the criteria of Wilson and Jungner than screening for HFP EF. Although convincing prognostically beneficial therapy for HFP EF is currently not yet available, one could argue that detecting HFP EF is useful. First of all, patients are correctly diagnosed and this prevents misclassification in other diseases that may also cause breathlessness and fatigue, such as COPD. Also, the possibility of adequately treating symptoms of breathlessness by managing incidental periods of volume overload with diuretics should not be undervalued. Finally, one could argue that the patient should at least be aware that he or she has a condition with a relatively poor prognosis.

### Time for a change

In many countries, including the Netherlands, T2DM patients are enrolled in disease management programs with

| Guidelines | Glucose/HbA1c levels/general aspects | Lipids/blood pressure/ nephropathy | Foot-control/neuropathy | Eye screening | Cardiovascular disease/risk |
|------------|------------------------------------|------------------------------------|-------------------------|--------------|-----------------------------|
| American Diabetes Association guidelines, update [11] | Determine HbA1c level at least twice a year | No clear recommendations | Perform an annual comprehensive foot examination to identify risk factors predictive of ulcers and amputations | Eye exam should be performed at least initially and at intervals (not further specified) | Cardiovascular risk factors (dyslipidaemia, hypertension, smoking, a positive family history of premature coronary disease, and the presence of albuminuria) should be assessed at least annually |
| Dutch GP guidelines on diabetes, update [13] | Three monthly control by a trained nurse practitioner: Well-being, the occurrence of episodes of hyperglycaemia or hyperglycaemia, problems with keeping to dietary and exercise recommendations, a check on the diabetes medication and adherence to drugs. Measurement of the fasting blood glucose level/HbA1C | Three monthly body weight and blood pressure | Three monthly inspection of feet to identify early signs of ulceration | Referral for fundus control 2-yearly and in patients with low degree of diabetic retinopathy annually [20, 21] | Annually assess presence of cardiovascular symptoms (which symptoms not further specified) and discuss lifestyle issues |
| NICE [16] | 2–6-monthly intervals until the blood glucose level is stable on unchanging therapy. 6-monthly assessments once the blood glucose level and blood glucose lowering therapy are stable | BP measurement at least annually in a person without previously diagnosed hypertension or renal disease | Make a formal enquiry annually about the development of neuropathic symptoms causing distress | Arrange or perform eye screening at, or around, the time of diagnosis | Review cardiovascular risk status annually by assessment of cardiovascular risk factors, including features of the metabolic syndrome and waist circumference, and change in personal or family cardiovascular history |
| European Association of Diabetes [18] | Annually: self-monitoring skills Offer and reinforce preventive lifestyle advice | Measure serum creatinine and estimate the glomerular filtration rate once a year | Review the issue of erectile dysfunction in men annually | Arrange repeat of structured eye surveillance annually | If the person is considered not to be at high cardiovascular risk, estimate annually using the UK Prospective Diabetes Study (UKPDS) risk engine [17] |
| ESC-EASD [19] | Glycaemic targets and glucose-lowering therapies must be individualised Diet, exercise and education remain the foundation of any type 2 diabetes management program (Intensive) glycaemic control should be appropriately applied in an individualised manner taking into account age, duration of T2DM and history of CVD. | No clear recommendations | No clear recommendations | No clear recommendations | No clear recommendations |

| | | Measure BP annually | No clear recommendations | No clear recommendations | Annual cardiovascular risk assessment and lifestyle management including diet and exercise |
a trained nurse practitioner playing a key role. Such programs are usually organised within the primary care setting. Routine assessments recommended in the current T2DM guidelines are: (1) glucose control, (2) blood pressure and lipid control, (3) early detection of retinopathy, (4) prevention of foot ulcers and (5) cardiovascular disease risk control and lifestyle management. See also Table 2.

Apart from the contents of routine assessments in patients with T2DM, also the frequency of such assessments continues to be discussed. The proposed frequency ranges from 1 to 4 times a year; however, a solid evidence-base for either of these recommendations is lacking [11–13]. Especially the high frequency of routine glucose measurements applied in current disease management programs has been questioned [14, 15]. Altogether, there seems to be room for substitution of care in the current disease management programs for T2DM patients. Less frequent routine consultations during the year, with less glucose measurements, and less frequent examinations of the feet and eyes, would create time for paying more attention to uncover latent cardiovascular disease, including heart failure.

Changing clinical practice

In view of the recent findings in the Netherlands, it seems worthwhile to merge specific screening for heart failure with the existing T2DM disease management programs. The high prevalence of unknown heart failure in patients aged ≥60 years, their reduced health status and prognosis justifies such merging. Nurse practitioners could specifically ask about shortness of breath or reduced exercise tolerance, ankle oedema, and nocturia. In suspected cases, the general practitioner could then check for signs of fluid overload (i.e. pulmonary crepitations, but also elevated jugular venous pressure and ankle oedema) followed by a blood test for B-type natriuretic peptide, and/or electrocardiography. Or, alternatively immediate referral for echocardiography [3].

Conclusions

Early detection of heart failure deserves more attention in the disease management programs of patients with T2DM. Specific screening could be merged with these programs.

To allow for an evidence-based choice of the frequency of screening for heart failure in T2DM patients or subgroups of these patients, cohort studies assessing the incidence of heart failure are required. Also, the exact aetiology of HfPEF should be unravelled because it could enable future prognostically beneficial therapy in these patients. General practitioners, internists and other health care professionals caring for these patients should become aware of the large risk of unknown heart failure in T2DM patients aged ≥60 years.

Funding Fonds NutsOhra (0702086) and Stichting Stoffels Hornstra.

Conflict of interests None declared.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Chiasson JL, Le LJ. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes. Lancet. 2014;384:1906–7.
2. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154–62.
3. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2015;17:187–95.
4. Boonman-de Winter LJ. Uncovering Heart Failure in Type 2 Diabetes. Utrecht: University Utrecht; 2015.
5. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–68.
6. Boonman-de Winter LJ, Hoes AW, Cramer MJ, de Jongh G, Jansen RR, Rutten FH. Prognosis of screen-detected heart failure with reduced and preserved ejection fraction in patients with type 2 diabetes. Int J Cardiol. 2015;185:162–4.
7. Wilson JM, Junger YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;65:281–393.
8. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.
9. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36:1718–27.
10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.
11. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
12. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab Vasc Dis Res. 2014;11:133–73.
13. Rutten GEHM, De Grauw WJC, Nijpels G, et al. The NHG guideline Diabetes mellitus type 2. Huisarts Wet. 2013;56:512–25.
14. Wermeling PR, Gorter KJ, Stellato RK, de Wit GA, Beulens JW, Rutten GE. Effectiveness and cost-effectiveness of 3-monthly versus 6-monthly monitoring of well-controlled type 2 diabetes patients: a pragmatic randomised controlled patient-preference equivalence trial in primary care (EFFIMODI study). Diabetes Obes Metab. 2014;16:841–9.
Advertisement placed here.
Advertisement placed here.
15. Ortiz Tobarra MT, Orozco Beltrán D, Gil Guillén V, Terol Moltó C. Frequency of attendance and degree of control of type-2 diabetic patients. Aten Primaria. 2008;40:139–44.
16. National Collaborating Centre for Chronic Conditions (UK). National clinical guideline for management in primary and secondary care (update) nice clinical guidelines, No. 66. London: Royal College of Physicians; 2008.
17. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9.
18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
19. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD; the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87.
20. Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol. 2007;91:1599–601.
21. Zavrelova H, Hoekstra T, Alssema M, et al. Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system West-Friesland, the Netherlands. Diabetes Care. 2011;34:867–72.

---

**CVOI E-learning formula!**

This is the CVOI e-learning article. The author has prepared 10 questions which are available through the website of the Cardiovascular Educational Institute (CVOI). Please follow the instructions below.

After finishing the questions you will be asked to fill in your name, hospital and e-mail address; then press the button 'verzenden'.

When 6 out of the 10 questions are answered correctly, you acquire 1 accreditation point granted by the Quality Committee of the Netherlands Society of Cardiology (NVVC). The acquired point will be credited to your personal file in the GAIA system. You will also receive an e-mail with all the correct answers.

Over a period of one year 10 e-learning articles will appear in 10 subsequent NHJ editions. In each edition the e-learning article will be recognisable by a special icon. On an annual basis you can collect 10 accreditation points. The accreditation points are credited in the GAIA system by the CVOI.

If you need additional information, please contact the CVOI by e-mail: cvoi@cvoi.org or by phone: 030-2345001.

E.E. van der Wall
Chief editor NHJ

K.B. Schick
Coordinator CVOI